Unleashing Immunotherapy by Targeting Cancer Stem Cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32763176.
- Also identified by DOI 10.1016/j.stem.2020.07.017 and PMC identifier 10249586.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Cell Stem Cell, Jia et al. (2020) identify residual cancer stem cells (CSCs) as a mechanism of immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC). Remarkably, targeting this population of CSCs can be exploited to potentiate immunotherapy and reduce tumor recurrence and metastasis.
Medical subject headings
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms